Overactive bladder Urological and Genital Diseases Other disorders of urinary system
Conditions
Interventions
Oral anticholinergic-antispasmodic (018) over a four-week open label phase.
Sponsors
Purdue Pharma Canada
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Males or non-pregnant, non-nursing females greater than or equal to 18 years of age 2. Diagnosis of overactive bladder and currently experiencing incontinent episodes and frequent micturitions or urgency 3. Newly diagnosed patients or patients not currently taking medication for overactive bladder 4. Capable of completing questionnaires in English or French
Exclusion criteria
Exclusion criteria: 1. Patient who will initiate treatment with any drug prescribed for the treatment of overactive bladder (except oestrogen) during the study period 2. Patient with a primary diagnosis of stress incontinence or a concurrent diagnosis of functional or overflow incontinence 3. Patients with conditions contra-indicating anticholinergic therapy or have hepatic or renal disease 4. Patients using an indwelling catheter or who had bladder electrostimulation therapy or participated in bladder training within the previous 14 days prior to study entry
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measured after four weeks of treatment: 1. Quality of life 2. Patient and physician satisfaction | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured after four weeks of treatment: 1. Tolerability 2. Cognitive status 3. Adverse events | — |
Countries
Canada
Outcome results
None listed